Drug Reference
Tislelizumab
PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
Fact box
- Therapeutic class
- PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
- Action class
- Programmed Death Receptor-1 Blocking Antibody
- Mechanism
- Programmed Death Receptor-1-directed Antibody Interactions
- Habit forming
- No
Brand names
Tevimbra
Available as
10 ML · Injection15 ML · Injection
No structured FDA label was available. Use the authoritative links below.
Authoritative sources
Reference only — not clinical advice. Verify against current FDA labeling and consult a licensed provider. About half of pediatric drug use is off-label and is not reflected in FDA labels; absence of pediatric information does not mean a medicine is unused or unsafe in children.